Table 2. Outcomes of the individual studies.
| Author | No. of cases | Peroral cases | Peranal cases | AP after DAE | Hyperamylasemia after DAE |
|---|---|---|---|---|---|
| Honda et al(9) | 13 | 13 | 0 | 1(7.7%) | 6 |
| Heine et al(10) | 275 | NA | NA | 3(1.1%) | NA |
| Mensink et al(11) | 2362 | 1207 | 412 | 7(0.3%) | NA |
| Kopáčová et al(12) | 35 | 35 | 0 | 1(2.9%) | 18 |
| Gerson et al(13) | 2413 | 1691 | 722 | 6(0.2%) | NA |
| Aktas et al(14) | 135 | 135 | 0 | 1(0.7%) | 22 |
| Pata et al(15) | 56 | 48 | 8 | 6(10.7%) | NA |
| Aktas et al(7) | 166 | 44 | 61 | 0(0%) | 13 |
| Nishimura et al(16) | 92 | 25 | 10 | 0(0%) | 0 |
| Zepeda-Gómez et al(17) | 92 | 92 | 0 | 3(3.3%) | 36 |
| Möschler et al(6) | 2245 | 1052 | 277 | 4(0.2%) | NA |
| Teshima et al(18) | 32 | 32 | 0 | 0(0%) | 6 |
| Shibuya et al(19) | 202 | 202 | 0 | 0(0%) | 140 |
| Itaba et al(20) | 44 | 44 | 0 | 1(2.3%) | 14 |
| Feng et al(21) | 20 | 12 | 8 | 0(0%) | 9 |
| Nakayama et al(22) | 538 | 295 | 243 | 5(09%) | NA |
| Tsujikawa et al(23) | 84 | 84 | 0 | 3(3.6%) | NA |
| Kopáčová et al(24) | 117 | 117 | 0 | 0(0%) | NA |
| Matsushita et al(25) | 96 | 96 | 0 | 1(1.0%) | 38 |
| Ivano et al(26) | 65 | NA | NA | 1(1.5%) | NA |
| Hagiwara et al(27) | 96 | 20 | 76 | 1(1.0%) | NA |
| Goenka et al(28) | 180 | 114 | 66 | 2(1.1%) | NA |
| Noujaim et al(29) | 1787 | 1514 | 270 | 1(0.1%) | NA |